Iodohippurate Sodium I 125 use while Breastfeeding

Iodohippurate Sodium I 125 Levels and Effects while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of iodohippurate sodium I 125 (ortho-iodohippurate sodium I 125; I 125 OIH) as a kidney function diagnostic agent. The United States Nuclear Regulatory Commission states that breastfeeding need not be interrupted after administration of I 125 OIH in doses up to 3 MBq (0.08 mCi) to a nursing mother.[1] However, some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 12 to 18 hours after the dose.[2][3] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[3][4][5]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[6]

Drug Levels

I 125 is a low-energy pure gamma emitter with a physical half-life of 60.14 days.[1] The effective half-life of I 125 OIH averages 4.8 hours.[6][7]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Iothalamate Sodium I 125

References

1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/

2. ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Annex D. Ann ICRP. 2008;38:163-84. PMID: 19154964

3. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PMID: 2645546

4. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.

5. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2006;25-7. http://www.arsac.org.uk

6. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203

7. Mountford PJ, Coakley AJ. Secretion of radioactivity in breast milk following administration of 123I hippuran. Br J Radiol. 1989;62:388-9. PMID: 2713603

Iodohippurate Sodium I 125 Identification

Substance Name

Iodohippurate Sodium I 125

CAS Registry Number

7230-65-1

Drug Class

Radiopharmaceuticals

Iodine Radioisotopes

Administrative Information

LactMed Record Number

669

Last Revision Date

20141107

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web2)